Conventional dose melphalan is inactive in metastatic melanoma: Results of an Eastern Cooperative Oncology Group Study (E1687)

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 245-248

  Hochster, Howard ^a,b   Strawderman, Myla Hunt ^a   Harris, Jules E ^a   Atkins, Michael B ^a   Oken, Martin ^a   Skeel, Roland T ^a   Jubelirer, Steven J ^a   Parkinson, David ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Eastern Cooperative Oncology Group; Melanoma; Melphalan

Indexed keywords

MELPHALAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0033042167     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00014     Document Type: Article

References (15)

1. Bergel F, Stock JA. Cytotoxic alpha amino acids and endopeptides. Br Emp Cancer Camp Annu Rep 1953; 3: 16.
2. Thatcher D, Lind M, Morgenstern G, et al. High dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 1989; 63: 1296-309.
3. Koeppler H, Pfleuger KH, Seitz R, Haveman K. High dose chemotherapy autologous bone marrow support in advanced malignant melanoma. Onkologie 1989; 12: 277-9.
4. Peters WP, Stewart A, Klotman M, et al. High dose combination of tyclophosphamide, cisplatin, and melphalan with autologous bone marrow support in clinical and pharmacologic study. Cancer Chemother Pharm 1989; 23: 377-83.
5. Lazrus HM, Herzig RH, Wolff SN, et al. Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantation. Cancer Treat Rep 1985; 69: 473.
6. Skene AI, Bulman AS, Williams GR, Thomas GM, Westbury G. Hyperthermic isolated regional perfursion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br. J Surg 1990; 77: 765-70.
7. Klaase JM, Kroon B, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115: 39-45.
8. Thompson JF, Hunt JA, Shannon KF, et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903-8.
9. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9: 2091-4.
10. Edwards MJ, Soon SJ, Boddie EW, Balch CM, McBride CM. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local exicision with isolated limb perfusion and wide local excision alone. Arch Surg 1990; 125: 317-321.
11. Koops HS, Vaglini M, Sucius S, et al. Prophylactic Isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998; 16: 2906-12.
12. Boros L, Peng YM, Albert DS, et al. Pharmacokinetics of very high dose oral melphalan in cancer patients. Am J Clin Oncol 1990; 13: 19-22.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
14. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc (A) 1972; 135: 185-98.
15. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B) 1972; 34: 187-220.